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ABSTRACT 
Background: Chronic pancreatitis (CP) is a risk factor of pancreatic adenocarcinoma (PA). The 
discovery of a pancreatic head lesion in CP frequently leads to perform a pancreaticoduodenectomy 
(PD) which preceded by a Multidisciplinary Meeting (MM) discussion. The aim of this study was to 
evaluate the relevance between this indication of PD and the definitive pathological results. 
Methods: Between 2000 and 2010, all patients with CP who underwent PD for suspicion of PA 
without any histological proof were retrospectively analyzed. The operative decision has always 
been taken in MM. The definitive pathological finding was retrospectively confronted with the 
MM’s decision, and patients were classified in two groups according to this concordance (group 1) 
or not (group2). Clinical and biological parameters were analyzed, preoperative imaging were 
reread, and confronted to pathological findings in order to identify predictive factors of malignant 
degeneration. 
Results: During the study period, 18 patients with CP had PD with 5 (27.7%) patients who had PA 
histologically confirmed (group1) and 13 (72.3%) who had not (group2). The median age was 52.5 
±8.2 years (sex ratio 3.5). The main symptoms were: pain (94.4%) and weight loss (72.2%).There 
was no postoperative mortality and morbidity was 61.1% (n=11) with 27.7% (n=5) of major 
complication (clavien-dindo classification ≥3).  . There was no statistical difference in clinical and 
biological parameters between the two groups. The rereading of imaging data could not detected 
efficiently all patients with PA. 
Conclusions: Our results confirm the difficulty encountered to detect malignant transformation in 
patients with CP before the surgery and therefore an elevated rate of unnecessary PD was found. A 




CP: chronic pancreatitis 
CT: computed tomography 
ERCP: endoscopic retrocholangiopancreatography 
EUS: endoscopic ultrasound 
FDG-PET: fluorodeoxyglucose positron emission tomography 
MM: multidisciplinary meeting 
MRCP: magnetic resonance cholangiopancreatography 
PA: pancreatic adenocarcinoma 
PD: pancreaticoduodenectomy 
ROC: receiver operator curve 
SD: standard derivation 
 
INTRODUCTION 
Chronic pancreatitis (CP) is a risk factor of pancreatic adenocarcinoma (PA), with a 5 and 10 years 
cumulative incidence in large cohort studies of 1.1% and 1.7% (1,2). The median 5-year survival 
rate after diagnosis of PA is 4-6% (all stages combined) (3,4), and surgery remains the only 
potential curative treatment (5), as current gemcitabline-based adjuvant chemotherapy protocols 
enable recurrence-free survival, reaching at best 23.5% and 16.5% at 3 and 5 years respectively (6).  
The diagnosis of PA is relatively simple in pancreatic body or tail, but is still difficult within a 
hypertrophic calcified head remodeled by CP. Then, the diagnosis of PA is often made only by 
imaging findings without histological proof related to the difficulty of obtaining adequate biopsy 
tissue with endoscopic ultrasound (EUS) (7). Nevertheless, the prognosis of malignant degeneration 
is so poor that PD is mandatory.  
The difficulty of this situation is to balance the risk of misdiagnosing a malignant transformation 
and the high morbidity (30-70%) associated with PD (8–10).  
In our center, surgical indication is always discussed in Multidisciplinary Meeting (MM). 
The main objective of this retrospective study was  to analyze the degree of concordance between 
indications of PD for PA in CP without histological proof and the definitive pathological finding.  
Secondary objectives were to identify preoperative clinical and biological factors that could be 
predictive of malignant degeneration, and to evaluate radiological expertise in this situation. 
PATIENTS AND METHODS 
Patients 
After approval by our institutional review board, all data of patients who underwent PD from 
January 2000 to December 2010 in our tertiary center of pancreatic surgery have been collected and 
retrospectively analyzed.  
Inclusion criteria were the presence of both CP and a focal head pancreatic lesion (either at 
diagnosis of CP or during follow-up), suspected to be a PA without histological proof (e.g EUS 
biopsies unrealizable or non-contributive). All indications of PD were established by MM with the 
participation of gastroenterologists, gastrointestinal surgeons and radiologists who reinterpreted 
patient’s imaging. The main criterion for decision process was based on imaging findings (contrast 
enhancement, presence of bulky lymph nodes and aspect of retroportal lamina). Thereby, patients 
diagnosed as PA based on preoperative histology were excluded. 
The clinical and biological data collected preoperatively were: age, gender, smoking habits, alcohol 
intake , symptoms, duration between the diagnosis of CP and the suspicion of PA, and blood work 
up results (aminotransferases, total and conjugated bilirubin, alkaline phosphatases, C-reactive 
protein). 
The preoperative imaging available was: endoscopic retrograde cholangiopancreatography (ERCP); 
upper gastrointestinal EUS; computed tomography (CT); magnetic resonance 
cholangiopancreatography (MRCP). FDG-PET scan was not used routinely in our center. 
The postoperative data analyzed were: length of hospital stay, morbidity, mortality and pathological 
findings. 
Definitions 
Postoperative mortality was defined as death during the hospital stay or within 30 days after 
surgery. Postoperative morbidity was defined according to the Clavien-Dindo classification (11). 
Postoperative complications included: pancreatic fistula classified into three groups according to the 
International Study Group of Pancreatic Fistula (ISGPF) criteria (12), delayed gastric emptying 
(DGE) classified according to the International Study Group of Pancreatic Surgery (ISGPS) criteria 
(13) but only with grade B and C retained for this study, as our center policy was to maintain the 
nasogastric tube until at least postoperative day-5, postpancreatectomy hemorrhage including intra- 
and extra luminal bleeding classified according to the ISGPS definition (14), and biliary fistula 
defined by biliary leakage  in  drains. 
Endpoints 
The main objective of our study was to analyze the degree of concordance between indications of 
PD for PA in CP without histological proof and the definitive pathological findings.  
Secondary objectives were to identify preoperative clinical and biological factors that could be 
predictive of malignant degeneration, and to evaluate radiological expertise in this situation. 
 
Methods 
The impact of the radiological expertise was measured by a secondary analysis of available imaging 
documents (presence or absence of PA) performed by 2 senior radiologists both specialized in 
abdominal imaging. The two radiologists were both blinded to the pathological data and the 
previous radiological reports. Expert status has been defined as an experience in abdominal imaging 
over 5 years. The preoperative imaging documents reviewed were CT, MRCP and ERCP. The 
radiologists paid a particular attention to pancreatic trophicity (head, body and tail), characteristics 
of main pancreatic and biliary ducts (size, regularity), characteristics of pancreatic head nodules 
(localization, size, aspect), aspect of retroportal lamina, presence of pancreatic calcifications and 
peripancreatic infiltration, pseudocyst or lymph nodes.  
Patients were divided into two groups according to pathological findings: group 1= CP + PA; group 
2= CP alone. Univariate analysis was used to identify clinical and biological factors which are 
predictive of PA. 
 
Statistical analysis 
Quantitative data were expressed as median (m) ± standard deviation (SD) and compared with 
Student’s t test or the Mann-Whitney test as appropriate. Qualitative data were expressed as 
numbers and percentages in each group of patients and compared with Fisher’s exact test. When a 
significant difference was found between the two groups, a receiver operator curve (ROC) was 
plotted to identify a threshold value. 
A p value <0.05 was considered statistically significant. Statistical analysis was carried out by 
MATLAB version 7.11 (MathWorks Inc. Natick, Massachussets). 
RESULTS 
A total of 314 patients underwent PD during the study period, including 18 (7.5%) patients with 
suspected PA on CP without preoperative histological confirmation. 
Clinical, biological and imaging findings 
The median age was 52.5 ±8.2 years. The sex ratio was 3.5. The median duration of follow-up for 
CP before suspicion of PA was 9.5 months. The underlying cause of CP was alcohol (n=12, 66.6%), 
cryptogenic (n=4, 22.2%) and genetic disease (n=2, 11.1%).  
The clinical signs were pain (n=17, 94.4%), weight loss (n=13, 72.2%), jaundice (n=8, 44.4%), 
asthenia (n=3, 16.6%), and glycemic disorder (n=1, 5.55%) (Table1).  Median levels of preoperative 
tumor biomarkers were 2.9 (range 1.7-6.9) and 13 (range 3-2056) for CEA and CA19.9, 
respectively. As these data were only available for 10 patients of the study population, we could not 
test them in the statistical analysis.  
The preoperative imaging analyzed were abdominal CT for 16 patients (88.8%), upper 
gastrointestinal EUS for 12 (66.6%), MRCP for 7 (38.8%) and ERCP for 5 (27.77%). 
The mean head nodule size (only available for 14 patients) was 1.8 ± 0.4 centimeters (range 1.2-
2.5). 
The EUS was particularly helpful in 10 cases: i) confirmed the presence of nodular lesions seen at 
CT scan or MRCP in 5 cases; ii) identified small nodular lesions in pancreatic head  (not seen by 
CT scan or MRCP) in 4 cases; iii) found 1 lymph node not seen with CT-scan in 1 case. 
The MRCP and ERCP were valuable in detecting main bile duct abnormalities. Indeed, ERCP 
identified:  2 irregularity and 3 strictures (complete in 1 case, and partial in 2 cases) of the main bile 
duct while MRCP identified 5 strictures (2 complete and 3 partial). 
Postoperative morbidity 
Postoperative complications are detailed in Table 2 and presented according to the Clavien 
classification in Table 3. There was no patient’s death. The overall morbidity was 61.1% including 
27.7% (n=5) patients with a major complication (Clavien ≥3). These complications required 
surgical reintervention for 4 patients (22.22%): 1 for hemorrhage, 1 for biliary, 1 for pancreatic 
fistula and 1 for both hemorrhage and biliary fistula. These 4 patients belonged to group 2. 
Gastrojejunal anastomosis bleeding occurred in one another patient from group 2 who was treated 
endoscopically. 
Pathology results 
The histological examination confirmed the presence of PA in 5 (27.7%) of the 18 patients. 
Predictive factors 
Univariate analysis revealed only one difference between the two groups: total bilirubin level was 
higher in group 1 (375 vs. 37 µmol/l) without statistical significance (p= 0.05) (Table 1). The 
threshold determined from the ROC curve (Fig. 1) was 355 µmol/l which gave 75 % sensibility and 
100 % specificity. 
Impact of the radiological expertise 
Only 14 patients (10 in group 1 and 4 in group 2) had available imaging for second radiological 
reading which could not detect all the patients with PA. The first radiologist concluded for presence 
of malignant lesions in 2 (14.3%) patients who actually had PA, 10 (71.4%) patients with benign 
lesions and could not conclude for 2 (14.3%) patients. The second radiologist concluded for 
presence of malignant lesions in 5 (35.7%) patients, including 3 who actually had PA, benign 
lesions in 7 (50%) patients and could not conclude for 2 (14.3%) patients.  
DISCUSSION 
Chronic pancreatitis is an independent risk factor for pancreatic adenocarcinoma. The cumulative 
risk of PA is 1.8% and 4% at 10 and 20 years respectively (15). To date, no guidelines have yet been 
published regarding the imaging follow-up(16,17), nevertheless this turning point in the evolution 
of CP justified to establish a radiological monitoring. The diagnosis of head localized PA is a 
serious challenge in patients with CP. This difficult situation represents 5.7% of the whole PD 
performed during the study period. 
Our analysis showed that most of these decisions were incorrect. Indeed, the pathological 
examinations of the surgical specimens revealed that 72.3% of these patients were PA free whereas 
it reach 5-9% without underlying CP (18,19). These inappropriate decisions had major 
consequences since the postoperative morbidity was 61.1 % (including 27.7% Clavien ≥3) for these 
patients. Similar rates have been previously reported (20). 
This hard decision-making process is hampered by the lack of informative clinical and biological 
data, as there are no specific signs differentiating PA and CP progression. In fact, our results showed 
no significant difference between our two groups in terms of clinical presentation as previously 
described (18,21). However, our results revealed higher levels of total bilirubin in the patients from 
group 2 at the limit of statistical significance (p=0.05). 
In addition, there is no consensus on tumor markers assay (22,23).  CA 19-9 would be the most 
sensitive marker but it can be valueless in context of cholestasis (24). To improve sensibility, some 
studies have proposed to associate K-ras gene mutation searching in the circulating DNA. The 
presence of this mutation, combined with an elevated CA19-9, would be associated with 95% 
sensibility (25,26). 
However, in clinical practice, radiological and EUS findings provides the key to diagnosis. For 
healthy pancreas, abdominal CT scan with IV contrast is the gold standard examination, both for 
diagnosis and disease spread (27). EUS is more sensitive, especially for small sized tumors, and 
also allows biopsy taking (28). However, in the context of CP, the sensibility of EUS is only 54-
74% (29,30). Nowadays, new EUS techniques associating enhanced contrast or elastography 
showed promising results but still need prospective studies to be validated (31,32). 
Because of the presence of parenchymatous calcifications and pancreatic head hypertrophy in CP, 
imaging interpretation is limited (33). In order to improve the sensibility of radiological 
explorations, specific magnetic resonance sequences (T1-weighted echo-gradient with gadolinium 
injection, T2-weighted turbo-spin echo) have been developed (34). Similarly, the response to 
secretin has been used to highlight diminished exocrine function due to apparently tumor-related 
stricture of the main pancreatic canal (35,36). Recently, diffusion magnetic resonance imaging has 
been tested in this indication and has shown significantly lower coefficients of diffusion in patients 
with PA (37). Small series have shown the potential usefulness of fluorodeoxyglucose positron 
emission tomography (FDG-PET) in this context with 83-86% sensibility (38, 39). 
Finally, due to the lack of imaging explorations specificity, Gerstenmaeir et al. proposed an 
evidence-based decision-making algorithm applying the statistical probabilities of pre- and post-
exam malignancy described in the literature (40). The algorithm starts with an abdominal CT 
followed by an MRCP if positive. No further exploration is necessary if both the CT and the MRCP 
are negative; a follow-up with a regular abdominal CT can be proposed. In case of positive MRCP, 
EUS is performed, followed by FDG-PET if it is negative. 
In our study, the rereading of images could not detect all the patients with PA although the 
radiologists had more time for interpretation and were free from the pressure of the MM. 
Nevertheless, the main limitation is that our study period is extended (10 years) and that all the 
different types of imaging were not available for all patients (explaining the lack of uniformly 
imaging protocol). The heterogeneity of the imaging protocols could explain the high number of 
false positive. Today, we perform in addition of systematic biomarkers assays (CA19.9 and CEA), 
the systematic realization of FDG-PET, diffusion MRI in order to improve the decision of MM. 
We expected to find a successful attitude that will limit the number of unnecessary PD, and 
eventually propose to these symptomatic patients an appropriate endoscopic or other surgical 
treatment (i.e. Frey or Beger procedure) which are associated with lower morbidity (10-30% and 
20-40% for the Frey and Beger procedure, respectively) (41,42) and improved long-term quality of 
life (43). 
  
In summary, our results were in line with the literature and confirmed the difficulty encountered to 
establish an accurate diagnosis of PA in CP. Consequently, the doubt about diagnosis leads to an 
over-indication of PD during the MM. This study confirms the necessity of a uniform validated 
imaging protocol to improve the decision making process in MM. 
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 All patients Group 1 Group 2 p 
Number of patients 18 5 (27.8%) 13 (72.2%)   
Age (years) 52.5 +/-8.2 55 +/-4.3 51 +/-9.3 0.45 
Gender Male 14 (77.7%) 5 (100%) 9 (69.2%) 0.27 
Female 4 (22.2%) 0  4 (30.8%)  
Symptoms Pain 17 (94.4%) 4 (80%) 13 (100%) 0.27 
Weight loss 13 (72.2%) 4 (80%) 9 (69.2%) 1 
Jaundice 8 (44.4%) 3 (60%) 5 (38.5%) 0.60 
Asthenia 3 (16.6%) 2 (40%) 1 (7.7%) 0.17 
Loss of glycemic control 1 (5.5%) 1 (20%) 0 0.27 
Weight loss (% of body mass) 5.19 6.94 4.58 0.29 
Smoking 16 (88.8%) 4 (80%) 12 (92.3%) 0.49 
Alcohol intake 13 (72.2%) 2 (40%) 11(84.6%)  0.09 
Time from diagnosis of CP and surgery 
(months) 
9.5 3 12 1 
Blood tests ASAT (UI/l) 50 77 47.5 0.62 
ALAT (UI/l) 83 106 76.5 0.59 
GGT (UI/l) 329.5 382 324 0.51 
Alkaline phosphatases (UI/l) 539 1510 525 0.23 
Total bilirubin (µmol/l) 43 375 37 0.05 
Conjugated bilirubin (µmol/l) 18 214.5 15 0.18 
 C-reactive protein (mg/l) 5 6 5 0.79 
 
Table 1: Preoperative clinical and biological data in the two groups of patients expressed as number, 
percentage and median +/- SD (group 1=CP+PA, group 2=CP); significance: p <0.05. 
 
 
  All patients Group 1 Group 2 
Delayed gastric emptying (at least grade B) 5 1 4 
Lymphorrhea 3 2 1 
Ascitis 1 0 1 
Transfusion 7 2 5 
Wall abscess 2 1 1 
Respiratory failure  1 0 1 
Functional obstruction  1 1 0 
Hemorrhage 3 0 3 
Pancreatic fistula 1 0 1 
Biliary fistula 3 0 3 
Revision surgery 4 0 4 
Death 0 0 0 
Length of hospital stay (days) 20.2+/-15.8 20.8+/-12.4 20 +/-17.4 
 
Table 2: Postoperative complications and duration of hospital stay (median ±SD).  
 
 
 Grade of Clavien-Dindo 
classification 
All patients Group 1 Group 2 
1 2 1 0 
2 4 1 3 
3 2 1 1 
4 3 0 3 
5 0 0 0 
Total 11 (61.1%) 3 9 
 




Figure 1: ROC of the total bilirubin rate for diagnosis of PA. 
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